Recent discoveries are helping scientists face this challenge in innovative ways. Studies have found that nearly a quarter of drugs that aren’t normally prescribed as antibiotics, such as medications ...

The QIDP status, granted by USFDA makes VRP-034 eligible for regulatory benefits including priority FDA review, potential ...

The Venus Remedies investigational product, VRP-034, has been granted QIDP designation by the US FDA for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adul ...

Venus Remedies’ novel polymyxin B formulation, VRP-034 gets US FDA QIDP designation: Our Bureau, Bengaluru Thursday, April 17, 2025, 12:15 Hrs [IST] Venus Remedies’ investigat ...

The human immune system is highly complex and well-equipped to combat most bacteria. However, in some instances bacteria can cause life-threatening infections and the increase of antibiotic-resistant ...

Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and ...

Directors intend to take up entitlements in part or in full in the Entitlement Offer ...

Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges, today announced that data from several new ...

Antimicrobial resistance is a global issue, making the search for a new generation of antibiotics imperative. Scientists ...

Oral Presentation: Efficacy and safety in a Phase 2 study of intravenous BV100 combined with polymyxin B versus best available therapy in adult subjects with ventilator associated bacterial pneumonia ...

While Africa contributes about 30% of global births, around 70% of the 287 000 global maternal deaths annually occur on this ...